<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096093</url>
  </required_header>
  <id_info>
    <org_study_id>ACIT-1-1001</org_study_id>
    <secondary_id>2012-005426-30</secondary_id>
    <nct_id>NCT03096093</nct_id>
  </id_info>
  <brief_title>Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer</brief_title>
  <official_title>A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Vaccines Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Liverpool University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Clatterbridge Cancer Centre NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Vaccines Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Vaccines Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates four different doses of ACIT-1 for safety and for the ability to raise&#xD;
      effective anti-cancer immune responses in patients with pancreatic and other cancers.&#xD;
      Approximately half of the patients will have pancreatic cancer and the other half will have&#xD;
      other cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immune system has an important role in helping prevent cancer by destroying early cancer&#xD;
      cells. When cancer does develop antigen-specific immune (T) cells are still present in the&#xD;
      blood but are either not responding or are not effective. Vaccines stimulate these T cells to&#xD;
      respond and kill cancer cells.&#xD;
&#xD;
      ACIT-1 is designed to stimulate tumour antigen-specific T cells to respond and kill cancer&#xD;
      cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>From start of treatment to 20 weeks.</time_frame>
    <description>Toxicity based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit</measure>
    <time_frame>From start of treatment up to 14 months.</time_frame>
    <description>Survival time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune responses</measure>
    <time_frame>Baseline, weeks 4, 8 and 20</time_frame>
    <description>Changes in tumour antigen specific immune responses in the blood compared to baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Cancer</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Immunotherapy - pancreatic cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with pancreatic or haematological cancer. Treatment will run concurrently with standard chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunotherapy - other late stage cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with other late stage cancers, not receiving any other standard treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACIT-1</intervention_name>
    <description>Cell suspension</description>
    <arm_group_label>Immunotherapy - other late stage cancers</arm_group_label>
    <arm_group_label>Immunotherapy - pancreatic cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignancy&#xD;
&#xD;
          -  Life-expectancy of 3 months or greater&#xD;
&#xD;
          -  Aged 18 years or above&#xD;
&#xD;
          -  Willing and able to give written informed consent for participation in the study&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0,1,2.&#xD;
&#xD;
          -  Absolute neutrophil count of ≥ 1 x 10e12/m3&#xD;
&#xD;
          -  Platelet count of at least 70 x 10e12/m3&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5x upper limit of normal; and aspartate transaminase/alanine&#xD;
             transaminase (AST/ALT) &lt; 5x upper limit of normal&#xD;
&#xD;
          -  Creatinine &lt; 1.5x upper limit of normal and/or glomerular filtration rate (GFR) &gt;&#xD;
             40ml/min&#xD;
&#xD;
          -  Female patients of child bearing potential and male patients whose partner is of child&#xD;
             bearing potential must be willing to ensure that they or their partner use effective&#xD;
             contraception during the study and for 3 months thereafter&#xD;
&#xD;
          -  Normal ECG measurements&#xD;
&#xD;
          -  Able (in the Investigators opinion) and willing to comply with all study requirements&#xD;
&#xD;
          -  Willing to allow his or her General Practitioner (GP) and consultant, if appropriate,&#xD;
             to be notified of participation in the study, and for the GP and/or the National&#xD;
             Cancer Registry to be contacted during follow up after the end of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent use of immunosuppressive drugs, in particular systemic steroid therapy,&#xD;
             above a threshold of 10mg per day prednisolone equivalent&#xD;
&#xD;
          -  Evidence of active infection e.g. Hepatitis B, Hepatitis C, HIV or syphilis&#xD;
&#xD;
          -  Chemotherapy, radiotherapy or biological therapy within 28 days of treatment with the&#xD;
             exception of standard of care chemotherapy for pancreatic and haematological cancer&#xD;
             patients&#xD;
&#xD;
          -  Participation in another investigational medicinal product trial within 28 days of&#xD;
             treatment&#xD;
&#xD;
          -  Other vaccination within previous 4 weeks&#xD;
&#xD;
          -  Antibody treatment within previous 3 months&#xD;
&#xD;
          -  Major surgery within the 14 days preceding the screening visit&#xD;
&#xD;
          -  Scheduled elective surgery or other procedures requiring general anaesthesia during&#xD;
             the study&#xD;
&#xD;
          -  Allogeneic graft transplantation recipient&#xD;
&#xD;
          -  Active systemic autoimmune and allergic disease&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Significant renal or hepatic impairment as defined by the following: Serum creatinine&#xD;
             ≥ 1.5 x upper limit of normal and/or GFR ≤ 40 ml/min. Total bilirubin ≥ 1.5 x upper&#xD;
             limit of normal; and AST/ALT ≥ 5 x upper limit of normal&#xD;
&#xD;
          -  Life threatening illness unrelated to the patient's cancer&#xD;
&#xD;
          -  Previous history of serious adverse allergic reaction to any medication&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participant at risk because of participation in the study, or may&#xD;
             influence the result of the study, or the participant's ability to participate in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel H Palmer, MBChB PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clatterbridge Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Rawcliffe</last_name>
    <phone>+44 (0)151 794 8167</phone>
    <email>acit1@liverpool.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Martin</last_name>
    <phone>+44 (0)151 794 8333</phone>
    <email>acit1@liverpool.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Bebington</city>
        <state>Wirral</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel H Palmer, MBChB PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic</keyword>
  <keyword>Late stage cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Phase I</keyword>
  <keyword>Vaccination</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

